PD-L1 Expression in Non-Clear Cell Renal Cell Cancer
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Clinical Pearls:
- In the past, it was thought that immune therapies worked better in clear-cell kidney cancer compared to non-clear cell kidney cancer
- A study found that non-clear cell tumors expressed PD-L1 on their tumor surface, begging the question if these patients might respond to PD-1 or PD-L1 antibodies
- Patients with non-clear cell tumors should be included in future trials that include PD-1 or PD-L1 antibodies
Recent Videos
Related Content
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024Podcast
In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
